ADMA Biologics, Inc. · 7.2/10 — Strong · Updated August 2026
Last updated: August 2026
Factor Snapshot
Invetso Quality Score
7.2 (Strong)
Core Drivers
Durable regulated demand with real barriers to entry: ADMA operates in a protected plasma-derived category with limited substitutes, meaningful regulatory barriers, and enough product differentiation to support persistent demand.
High capital productivity and disciplined reinvestment: Strong returns on capital and a conservative balance sheet indicate the business can fund growth internally without relying on aggressive financing.
Management has translated execution into profitable scale: Leadership has shown a consistent ability to turn operating improvements into stronger profitability and balance-sheet stability, which improves confidence in continued execution.
Key Constraints
Scalability is constrained by plasma supply and manufacturing throughput: Growth depends on physical collection, fractionation, and compliance capacity, so the business cannot compound like an asset-light model and trails larger plasma peers on scale.
Working-capital intensity limits flexibility: A very long cash conversion cycle ties up cash and reduces reinvestment speed, which is a meaningful drag versus more efficient competitors.
Peer-relative moat is solid but not dominant: ADMA has a defensible niche, but it lacks the scale, ecosystem control, and diversification of the strongest global plasma leaders, which caps upside asymmetry.
Synthesis
ADMA presents a quality profile that is better than average, anchored by a defensible regulated market, strong capital productivity, and management that has executed with discipline. The most important positive is that the business can convert capital into returns without balance-sheet strain, which supports ongoing reinvestment and reduces downside from financing risk. The main reason the score does not move higher is that growth is still constrained by plasma supply, manufacturing throughput, and heavy working-capital needs, so the company cannot scale with the same ease as the best global peers. That makes the upside real but not open-ended, because expansion depends more on operational execution than on a structurally scalable model. Relative to global peers, ADMA looks above average, but not leading. The result is an investment profile with durable fundamentals and manageable risk, yet with clear limits on how fast the business can compound.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on ADMA Biologics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

